ECHA OR Inspections 2026: How Non-EU Manufacturers Can Prepare

## ECHA Inspections 2026: A Guide for Non-EU Manufacturers on Selecting a REACH Only Representative With the European Chemicals Agency (ECHA) gearing up for a 2026 enforcement project focused on Only Representatives (OR), non-EU manufacturers face heightened scrutiny of their EU REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) compliance. For companies, including medical device manufacturers whose products contain chemical substances requiring registration, the selection of a competent and diligent Only Representative is no longer just a procedural step—it is a critical strategic decision. A robust OR is the manufacturer’s legal presence in the EU, responsible for fulfilling all obligations of an importer and ensuring long-term compliance. This article provides a comprehensive framework for non-EU manufacturers to establish a rigorous process for selecting, qualifying, and managing a REACH Only Representative. It moves beyond a surface-level checklist to explore the operational depth, technical expertise, and contractual safeguards necessary to build a resilient compliance partnership and confidently prepare for future regulatory inspections. ### Key Points * **Legal Responsibility:** The Only Representative is not merely an agent; they are a legal entity within the EU that assumes full responsibility and liability for fulfilling the REACH obligations of the non-EU manufacturer they represent. * **Beyond Registration:** A qualified OR provides ongoing compliance management, not just a one-time registration. This includes dossier maintenance, Safety Data Sheet (SDS) updates, volume tracking, and communication with downstream users and ECHA. * **Technical Expertise is Non-Negotiable:** Manufacturers must verify an OR's experience with similar substance types and their proven ability to manage Substance Information Exchange Forums (SIEFs), lead registrant roles, and complex data-sharing negotiations. * **Scrutinize Compliance Systems:** A key part of due diligence is assessing the OR’s internal systems for tracking tonnage bands, updating regulatory documentation, and managing supply chain communications. These systems will be a primary focus of ECHA inspections. * **Contractual Clarity is Essential:** The legal agreement must clearly define roles, responsibilities, data ownership, liability, and procedures for transferring the OR role. A poorly defined contract creates significant compliance risk. * **Proactive Preparation is Key:** With ECHA’s 2026 inspections on the horizon, manufacturers should review their current OR relationships or initiate a thorough selection process now to ensure their compliance framework is secure and defensible. ### Understanding the Critical Role of the Only Representative Under REACH Regulation (EC) No 1907/2006, any company based outside the European Union that manufactures substances, formulates mixtures, or produces articles that are imported into the EU must ensure those substances are registered with ECHA. To facilitate this, the regulation allows a non-EU manufacturer to appoint an "Only Representative." The OR is a natural or legal person established physically within the EU who takes on the tasks and responsibilities of importers. This relieves the actual EU importers in that supply chain from their registration obligations for the substances covered by the OR. However, this appointment carries significant legal weight. The OR is fully liable for complying with all importer obligations for the substances they represent. During an ECHA inspection, the OR’s records, systems, and processes are the primary target of investigation. For a non-EU manufacturer, this means that any compliance failure by their OR is treated as their own failure, potentially leading to market access denial, financial penalties, and significant reputational damage. ### A Framework for Vetting and Qualifying an OR Partner Selecting an OR should be treated with the same rigor as selecting a critical component supplier. A comprehensive evaluation process can be broken down into three phases: initial screening, deep-diligence auditing, and contractual negotiation. #### Phase 1: Initial Screening Before engaging in deep discussions, manufacturers can perform an initial screening of potential OR providers to create a shortlist. * **Industry Specialization:** Does the OR have experience with the medical device industry or other highly regulated sectors? They should understand the specific challenges related to substances in articles, biocompatibility, and complex supply chains. * **Scope of Services:** Look for providers who offer a full suite of services beyond basic registration, including dossier updates, SDS authoring, SIEF management, and regulatory monitoring. Avoid providers who appear to be simple "postbox" services. * **Longevity and Reputation:** How long has the firm been providing OR services? Can they provide references or anonymized case studies demonstrating their track record? #### Phase 2: Deep-Diligence Auditing Once a shortlist is created, the manufacturer must conduct a thorough audit of the potential OR’s capabilities. This involves requesting specific evidence and asking detailed operational questions. **Key Areas to Investigate:** 1. **Regulatory and Technical Expertise** * **Substance Experience:** Request evidence of their experience registering substances chemically similar to yours. Ask about their technical staff's qualifications (e.g., toxicologists, chemists). * **SIEF Management:** How do they handle SIEF communications and negotiations? Ask for their standard operating procedures (SOPs) for managing data sharing, cost disputes, and lead registrant interactions. * **Dossier Quality:** Inquire about their process for preparing and maintaining registration dossiers. Do they have a robust quality management system (QMS) for document control? This is analogous to the stringent documentation practices required under medical device regulations like those in 21 CFR Part 820. 2. **Compliance Management Systems** * **Volume Tracking:** Request a demonstration of their system for tracking imported substance volumes against registered tonnage bands. How do they collect this data from the non-EU manufacturer and its various EU importers? The system must be robust enough to prevent accidental overages. * **Documentation Maintenance:** How do they ensure registration dossiers and SDSs are kept up-to-date with new scientific data, changes in classification and labelling (CLP), or new regulatory requirements? This is a critical area for inspection. * **Supply Chain Communication:** What is their process for communicating requirements from downstream users back to the non-EU manufacturer? A compliant OR must facilitate this two-way communication flow. #### Phase 3: Contractual Negotiation and Onboarding The legal agreement with the OR is the foundation of the relationship. It must be detailed and unambiguous. **Essential Contractual Provisions:** * **Clear Scope of Responsibilities:** Explicitly list all duties, including dossier submission, maintenance, SIEF participation, volume tracking, and communication with authorities. * **Data Ownership and Access:** The contract should state that the non-EU manufacturer owns all data and the registration number. It must include a clause guaranteeing the immediate transfer of all data and the OR role upon request. * **Liability and Indemnification:** Clearly define the liability of each party. The OR should hold adequate professional liability insurance. * **Confidentiality:** Include strong non-disclosure provisions to protect sensitive business and chemical information. * **Termination and Transferability:** Outline a clear process for terminating the agreement and transferring the OR role to another provider, ensuring business continuity. This should include a commitment from the outgoing OR to fully cooperate with the transfer process. ### Scenarios: The Impact of OR Selection To illustrate the importance of this process, consider two common scenarios. #### Scenario 1: The "Postbox" Representative A non-EU manufacturer chooses an OR based solely on the lowest cost. The OR performs the initial registration but lacks robust systems for ongoing management. They do not proactively track substance volumes or update the SDS when new toxicological data emerges. During a 2026 inspection, ECHA discovers the dossier is outdated and the imported tonnage has exceeded the registered band. The non-EU manufacturer faces immediate enforcement action, potential disruption of their EU supply chain, and must undertake a costly and urgent project to find a new OR and remediate the non-compliance. #### Scenario 2: The Strategic Compliance Partner A manufacturer conducts thorough due diligence and selects an OR with proven expertise in their substance category. The OR uses a sophisticated software portal to track import volumes in near-real-time. Their regulatory team monitors ECHA updates and proactively informs the manufacturer about a new substance evaluation, advising on the need for additional testing data well in advance. When ECHA announces its inspection, the OR has all documentation organized and readily available. The inspection proceeds smoothly, confirming the manufacturer’s compliant status in the EU market. ### Finding and Comparing REACH Only Representative Providers The process of identifying and vetting multiple OR candidates can be time-consuming. Using a specialized directory allows manufacturers to efficiently compare providers who have already undergone a preliminary screening process. When evaluating options, focus on their demonstrated experience, the depth of their compliance systems, and their ability to act as a long-term strategic partner. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/reach_only_rep) and request quotes for free. ### Key Regulatory References When navigating complex regulatory landscapes, it is crucial to rely on official documentation. For REACH compliance, key documents include: - REACH Regulation (EC) No 1907/2006 (the foundational legal text). - ECHA Guidance on Registration. - ECHA Guidance for Articles. While REACH governs the EU, manufacturers familiar with the U.S. system will recognize the importance of foundational regulations and official guidance documents in clarifying compliance expectations. For example, in the U.S., medical device compliance is outlined in detail within the Code of Federal Regulations (e.g., under 21 CFR) and further explained in extensive FDA guidance documents. This principle of relying on primary legal texts and agency guidance is a universal best practice in regulatory affairs. *** This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*